A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer

Published:2013-01 Issue:1 Volume:14 Page:19-27
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ellis Peter M.,Chu Quincy S.,Leighl Natasha,Laurie Scott A.,Fritsch Holger,Gaschler-Markefski Birgit,Gyorffy Steve,Munzert Gerd

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

2. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

3. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

4. Targeting cell cycle kinases and kinesins in anticancer drug development;Yap;Expert Opin Drugs Discov,2007

5. Polo on the rise-from mitotic entry to cytokinesis with Plk1;Petronczki;Dev Cell,2008

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells;Oncology Letters;2024-05-14

2. The two sides of chromosomal instability: drivers and brakes in cancer;Signal Transduction and Targeted Therapy;2024-03-29

3. Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis;Frontiers in Oncology;2023-02-09

4. Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential;Journal of Medicinal Chemistry;2022-07-25

5. Present and Future Perspective on PLK1 Inhibition in Cancer Treatment;Frontiers in Oncology;2022-06-02